Literature DB >> 35004946

Molecular characterization of circulating tumor cells in pancreatic ductal adenocarcinoma: potential diagnostic and prognostic significance in clinical practice.

Xudong Zhao1, Yongsu Ma1, Xiu Dong2, Zhengkui Zhang1, Xiaodong Tian1, Xiaohang Zhao2, Yinmo Yang1.   

Abstract

BACKGROUND: The clinical value of heterogeneous sub-populations of circulating tumor cells (CTCs) in pancreatic ductal adenocarcinoma (PDAC) remains unclear.
METHODS: Peripheral blood samples were obtained from 67 PDAC patients. CTCs were isolated by employing CD45 negative enrichment technique and further characterized for epithelial to mesenchymal transition (EMT) or human equilibrative nucleoside transporter-1 (hENT-1). The relationships between CTCs sub-phenotypes with clinicopathological factors or post-operative recurrence in PDAC patients were analyzed.
RESULTS: EMT related CTCs could be isolated and identified from the 81% of patients (54/67), and both the total count (median: 5 vs. 17/mL, P<0.0001) and M-CTC percentage (median: 0.2 vs. 0.345, P=0.0244) of CTCs could differentiate local/regional with metastatic disease. Multivariate analysis showed that both AJCC stage (P=0.025) and M-CTC percentage (P=0.001) were independent prognostic indicators of recurrence free survival (RFS) in resected patients. Moreover, Kaplan-Meier survival analysis showed that M-CTC after 2 courses of chemotherapy was significantly associated with inferior RFS (49.5 weeks vs. undefined, P=0.0288). No significant correlation in hENT-1 expression was found between CTCs and matched tumor tissues, and further multivariate analysis suggested hENT-1 expression in CTCs as independent prognostic factor for RFS (P=0.016). Patients with low hENT-1 expression in CTCs had decreased RFS (32 weeks vs. undefined, P=0.0337).
CONCLUSIONS: CTCs could be the promising diagnostic biomarkers in PDAC patients, and phenotypic profiling of CTCs based on EMT or hENT-1 could help establish novel prognostic biomarkers in resected patients undergoing adjuvant gemcitabine-based chemotherapy. KEYWORDS: Circulating tumor cells (CTCs); Pancreatic ductal adenocarcinoma (PDAC); Epithelial to mesenchymal transition (EMT); human equilibrative nucleoside transporter-1 (hENT-1). 2021 Hepatobiliary Surgery and Nutrition. All rights reserved.

Entities:  

Year:  2021        PMID: 35004946      PMCID: PMC8683903          DOI: 10.21037/hbsn-20-383

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


  51 in total

1.  PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer.

Authors:  Athina Markou; Sofia Farkona; Christina Schiza; Tonia Efstathiou; Sophia Kounelis; Nikos Malamos; Vassilis Georgoulias; Evi Lianidou
Journal:  Clin Cancer Res       Date:  2014-11-15       Impact factor: 12.531

2.  Is early-stage pancreatic adenocarcinoma truly early: stage migration on final pathology with surgery-first versus neoadjuvant therapy sequencing.

Authors:  Andrew J Lee; Eve Simoneau; Yi-Ju Chiang; Jeffrey E Lee; Michael P Kim; Thomas A Aloia; Jean-Nicolas Vauthey; Matthew H Katz; Ching-Wei D Tzeng
Journal:  HPB (Oxford)       Date:  2019-02-22       Impact factor: 3.647

3.  Cytologic characteristics of circulating epithelioid cells in pancreatic disease.

Authors:  Matthew W Rosenbaum; Christy E Cauley; Birte Kulemann; Andrew S Liss; Carlos Fernandez-Del Castillo; Andrew L Warshaw; Keith D Lillemoe; Sarah P Thayer; Martha B Pitman
Journal:  Cancer Cytopathol       Date:  2017-03-03       Impact factor: 5.284

4.  Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer.

Authors:  Tao Wei; Xiaoyu Zhang; Qi Zhang; Jiaqi Yang; Qi Chen; Jianxin Wang; Xiang Li; Junye Chen; Tao Ma; Guogang Li; Shunliang Gao; Jianying Lou; Risheng Que; Yi Wang; Xiaowei Dang; Lei Zheng; Tingbo Liang; Xueli Bai
Journal:  Cancer Lett       Date:  2019-03-21       Impact factor: 8.679

5.  Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.

Authors:  Naoya Nakagawa; Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Naru Kondo; Taijiro Sueda
Journal:  Surgery       Date:  2012-12-17       Impact factor: 3.982

6.  Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients.

Authors:  Giovanni Brandi; Marzia Deserti; Francesco Vasuri; Andrea Farioli; Alessio Degiovanni; Andrea Palloni; Giorgio Frega; Maria A Barbera; Stefania de Lorenzo; Ingrid Garajova; Mariacristina Di Marco; Antonio D Pinna; Matteo Cescon; Alessandro Cucchetti; Giorgio Ercolani; Antonietta D'Errico-Grigioni; Maria A Pantaleo; Guido Biasco; Simona Tavolari
Journal:  Oncologist       Date:  2016-03-31

7.  Cancer. Circulating tumor cells.

Authors:  Vicki Plaks; Charlotte D Koopman; Zena Werb
Journal:  Science       Date:  2013-09-13       Impact factor: 47.728

8.  Identification of the tumour transition states occurring during EMT.

Authors:  Ievgenia Pastushenko; Audrey Brisebarre; Alejandro Sifrim; Marco Fioramonti; Tatiana Revenco; Soufiane Boumahdi; Alexandra Van Keymeulen; Daniel Brown; Virginie Moers; Sophie Lemaire; Sarah De Clercq; Esmeralda Minguijón; Cédric Balsat; Youri Sokolow; Christine Dubois; Florian De Cock; Samuel Scozzaro; Federico Sopena; Angel Lanas; Nicky D'Haene; Isabelle Salmon; Jean-Christophe Marine; Thierry Voet; Panagiota A Sotiropoulou; Cédric Blanpain
Journal:  Nature       Date:  2018-04-18       Impact factor: 49.962

9.  Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer.

Authors:  J S Ankeny; C M Court; S Hou; Q Li; M Song; D Wu; J F Chen; T Lee; M Lin; S Sho; M M Rochefort; M D Girgis; J Yao; Z A Wainberg; V R Muthusamy; R R Watson; T R Donahue; O J Hines; H A Reber; T G Graeber; H R Tseng; J S Tomlinson
Journal:  Br J Cancer       Date:  2016-06-14       Impact factor: 7.640

10.  Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis.

Authors:  Xiao Liu; Junjian Li; Bruno Loureiro Cadilha; Anamarija Markota; Cornelia Voigt; Zhe Huang; Peter P Lin; Daisy D Wang; Juncheng Dai; Gisela Kranz; Anna Krandick; Darko Libl; Horst Zitzelsberger; Isabella Zagorski; Herbert Braselmann; Min Pan; Sibo Zhu; Yuanchi Huang; Sebastian Niedermeyer; Christoph A Reichel; Bernd Uhl; Daria Briukhovetska; Javier Suárez; Sebastian Kobold; Olivier Gires; Hongxia Wang
Journal:  Sci Adv       Date:  2019-06-19       Impact factor: 14.136

View more
  3 in total

1.  Hidden-mortality risk among patients deemed "low-risk" following high-risk operations.

Authors:  Yongliang Sun; Wenquan Niu; Zhiying Yang
Journal:  Hepatobiliary Surg Nutr       Date:  2022-04       Impact factor: 8.265

2.  The management strategy of pancreatic cancer in the era of systemic therapy-"Surgery First" or "Surgery Last"?

Authors:  Yinmo Yang; Xiaodong Tian
Journal:  Hepatobiliary Surg Nutr       Date:  2022-08       Impact factor: 8.265

3.  ALCAM: A Novel Surface Marker on EpCAMlow Circulating Tumor Cells.

Authors:  Rossana Signorelli; Teresa Maidana Giret; Oliver Umland; Marco Hadisurya; Shweta Lavania; John Lalith Charles Richard; Ashley Middleton; Melinda Minucci Boone; Ayse Burcu Ergonul; Weiguo Andy Tao; Haleh Amirian; Anton Iliuk; Aliya Khan; Robert Diaz; Daniel Bilbao Cortes; Monica Garcia-Buitrago; Harrys Kishore Charles Jacob
Journal:  Biomedicines       Date:  2022-08-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.